RBC initiated coverage of Grail with a Sector Perform rating and $84 target, citing Galleri’s potent

On Wednesday, GRAIL (NASDAQ:GRAL) discussed second-quarter financial results during its earnings cal

RBC Capital analyst Dan Leonard initiates coverage on GRAIL (NASDAQ:GRAL) with a Sector Perform r

GRAIL, Inc. (GRAL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

UBS analyst Doug Schenkel initiates coverage on GRAIL (NASDAQ:GRAL) with a Buy rating and announc

Concurrent Investment Advisors LLC raised its stake in GRAIL, Inc. (NASDAQ: GRAL) by 65.8% in the se

The transaction was valued at approximately $672,000. The shares traded represented 3% of the direct

FDA approval is crucial for Galleri's adoption by insurers. The company received some good news from

SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company wh

MENLO PARK, Calif., Aug. 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company w

GRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer ear

Bank of America Corp DE raised its holdings in shares of GRAIL, Inc. (NASDAQ: GRAL) by 29.0% during

GRAIL faces a binary FDA approval event for Galleri, with significant stock movement expected based

GRAIL Inc. (NASDAQ:GRAL) on Friday said it is preparing for a pivotal regulatory event as the U.S. F

The FDA's advisory committee will meet on September 23 to review the PMA application for GRAIL&#

GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Gall

Grail said on Friday the U.S. FDA ​plans to hold a ‌meeting of outside experts to review its multi-c

GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can

MENLO PARK, Calif., Aug. 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company wh

GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript

GRAIL NASDAQ: GRAL reported second-quarter revenue growth driven by higher Galleri test volumes, whi

GRAIL (NASDAQ:GRAL) reported quarterly losses of $(2.56) per share which beat the analyst consensus

Q2 Galleri ® Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has

NEW YORK--(BUSINESS WIRE)---- $GRAL #ClassAction--Faruqi & Faruqi, LLP, a leading national securitie

New York, New York--(Newsfile Corp. - August 4, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nati

NEW YORK, Aug. 4, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholder

GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can

Mizuho analyst Bradley Bowers maintains GRAIL (NASDAQ:GRAL) with a Neutral and raises the price t

Goldman Sachs analyst Evie Koslosky initiates coverage on GRAIL (NASDAQ:GRAL) with a Neutral rati

TD Cowen analyst Dan Brennan maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target

Piper Sandler analyst David Westenberg maintains GRAIL (NASDAQ:GRAL) with a Neutral and raises th

GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can

Wall Street analysts changed outlook on top stocks. See rating changes on NKE, SMPL, WSR, NTNX, and

Top Wall Street analysts changed outlook on top names. Initiations & upgrades noted. For full ch

Mizuho analyst Bradley Bowers initiates coverage on GRAIL (NASDAQ:GRAL) with a Neutral rating and

Piper Sandler analyst David Westenberg initiates coverage on GRAIL (NASDAQ:GRAL) with a Neutral r

GRAIL stock rises after Epic partnership expands Galleri test access; trial shows Stage IV reduction

Integration Will Enable Approximately 450 Health Systems to Access the Galleri Test Results Within T

Guggenheim analyst Subbu Nambi maintains GRAIL (NASDAQ:GRAL) with a Buy and lowers the price targ

The Supreme Court struck down President Donald Trump's global tariffs, ruling IEEPA does not aut

(Editor's note: The future prices of benchmark tracking ETFs, the lede, and the headline were up